Luteolin-Mediated Inhibition of Hepatic Stellate Cell Activation via Suppression of the STAT3 Pathway
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Hepatic stellate cell (HSC) activation is responsible for hepatic fibrogenesis and is associated with an overexpression of transcription 3 (STAT3). Luteolin, a common dietary flavonoid with potent anti-inflammatory properties, has previously demonstrated antifibrogenic properties in HSCs but the mechanism has not been fully elucidated. Activated human and rat hepatic stellate cell lines LX-2 and HSC-T6 were used to study the effects of luteolin on HSCs. Cellular proteins were determined by western blot and immunofluorescence. Cell proliferation was assessed with Alamar Blue assay. Luteolin significantly decreased LX-2 and HSC-T6 cell viability in a time-and-dose-dependent manner, as well as decreased HSC end-products α-smooth muscle actin (α-SMA), collagen I, and fibronectin. Luteolin decreased levels of total and phosphorylated STAT3, suppressed STAT3 nuclear translocation and transcriptional activity, and attenuated expression of STAT3-regulated proteins c-myc and cyclin D1. STAT3 specific inhibitors stattic and SH-4-54 demonstrated similar effects on HSC viability and α-SMA production. In LX-2 and HSC-T6 cells, luteolin demonstrates a potent ability to inhibit hepatic fibrogenesis via suppression of the STAT3 pathway. These results further elucidate the mechanism of luteolin as well as the effect of the STAT3 pathway on HSC activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106 · cited 4×
“Luteolin has been shown to have antifibrogenic effects in activated HSCs, though the mechanism has not been fully elucidated [16,19].”
BackgroundInfluentialStattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Mechanisms of hepatic fibrogenesis
Lee, U. E., & Friedman, S. L. (2011) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2011.02.005 · Cited by 923
Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice
Kong, X., Feng, D., Wang, H., Hong, F., Bertola, A., Wang, F.-S., & Gao, B. (2012) · Hepatology · doi:10.1002/hep.25744 · Cited by 448
Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production
Ogata, H., Chinen, T., Yoshida, T., Kinjyo, I., Takaesu, G., Shiraishi, H., Iida, M., Kobayashi, T., & Yoshimura, A. (2006) · Oncogene · doi:10.1038/sj.onc.1209281 · Cited by 246 · cited 1×
“The overexpression of STAT3 in hepatic fibrosis may have model-dependent and cell-specific functions [41,42].”
BackgroundXiang, D.-M., Sun, W., Ning, B.-F., Zhou, T.-F., Li, X.-F., Zhong, W., Cheng, Z., Xia, M.-Y., Wang, X., Deng, X., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313392 · Cited by 229 · cited 2×
“This is consistent with other studies that have demonstrated that the STAT3 pathway is an important player in HSC activation and that STAT3 represents a potential therapeutic target for antifibrogenic therapy [13,34,35].”
BackgroundResultSelf-citationInteractions Between Hepatic Stellate Cells and the Immune System
Maher, J. J. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17555 · Cited by 198
Haftchenary, S., Luchman, H. A., Jouk, A. O., Veloso, A. J., Page, B. D. G., Cheng, X. R., Dawson, S. S., Grinshtein, N., Shahani, V. M., Kerman, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4003138 · Cited by 126
Su, T.-H., Shiau, C.-W., Jao, P., Liu, C.-H., Liu, C.-J., Tai, W.-T., Jeng, Y.-M., Yang, H.-C., Tseng, T.-C., Huang, H.-P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1507499112 · Cited by 78 · cited 2×
“This is consistent with other studies that have demonstrated that the STAT3 pathway is an important player in HSC activation and that STAT3 represents a potential therapeutic target for antifibrogenic therapy [13,34,35].”
BackgroundResultHuang, Y., Qiu, J., Dong, S., Redell, M. S., Poli, V., Mancini, M. A., & Tweardy, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704548200 · Cited by 65
Cited by
Saha, P., Talukdar, A. D., Nath, R., Sarker, S. D., Nahar, L., Sahu, J., & Choudhury, M. D. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00509 · Cited by 148
Ashour, A. A., El-Kamel, A. H., Mehanna, R. A., Mourad, G., & Heikal, L. A. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2142700 · Cited by 60
Extracellular vesicles: emerging therapeutic agents for liver fibrosis
Chiabotto, G., Semnani, A., Ceccotti, E., & Bruno, S. (2025) · Extracellular Vesicles and Circulating Nucleic Acids · doi:10.20517/evcna.2025.08 · Cited by 13
Metadata
- Authors
- Cummins, C. B., Wang, X., Nunez Lopez, O., Graham, G., Tie, H.-Y., Zhou, J., & Radhakrishnan, R. S.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2018-05-24
- Volume
- 19
- Issue
- 6
- Pages
- 1567
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2803935258
- Cited by
- 40
- References
- 10
- FWCI
- 2.00
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.